Beam Therapeutics annual operating cash flow
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Operating Cash Flow Growth & History (BEAM)
Beam Therapeutics's operating cash flow was −$345.1M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$345.1M | $2.1M | — |
| 2024 | 2024-12-31 | −$347.2M | −$198.1M | — |
| 2023 | 2023-12-31 | −$149.2M | −$171.7M | — |
| 2022 | 2022-12-31 | $22.5M | $88.8M | — |
| 2021 | 2021-12-31 | −$66.3M | $29.5M | — |
| 2020 | 2020-12-31 | −$95.7M | −$23.7M | — |
| 2019 | 2019-12-31 | −$72.0M | — | — |
Beam Therapeutics quarterly operating cash flow
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$66.1M | $10.4M | — |
| Q1 2026 | 2026-03-31 | −$128.5M | −$24.6M | — |
| Q4 2025 | 2025-12-31 | −$83.3M | −$6.9M | — |
| Q3 2025 | 2025-09-30 | −$81.5M | $6.6M | — |
| Q2 2025 | 2025-06-30 | −$76.5M | $6.6M | — |
| Q1 2025 | 2025-03-31 | −$103.9M | −$4.1M | — |
| Q4 2024 | 2024-12-31 | −$76.4M | −$211.4M | — |
| Q3 2024 | 2024-09-30 | −$88.1M | $1.7M | — |
| Q2 2024 | 2024-06-30 | −$83.0M | $1.7M | — |
| Q1 2024 | 2024-03-31 | −$99.7M | $10.1M | — |
| Q4 2023 | 2023-12-31 | $135.1M | $204.3M | — |
| Q3 2023 | 2023-09-30 | −$89.8M | −$15.3M | — |
| Q2 2023 | 2023-06-30 | −$84.7M | −$32.4M | — |
| Q1 2023 | 2023-03-31 | −$109.8M | −$328.3M | — |
| Q4 2022 | 2022-12-31 | −$69.2M | −$71.0M | — |
| Q3 2022 | 2022-09-30 | −$74.5M | −$77.5M | — |
| Q2 2022 | 2022-06-30 | −$52.3M | −$19.7M | — |
| Q1 2022 | 2022-03-31 | $218.5M | $257.1M | — |
| Q4 2021 | 2021-12-31 | $1.8M | $26.1M | — |
| Q3 2021 | 2021-09-30 | $3.0M | $24.2M | — |
| Q2 2021 | 2021-06-30 | −$32.5M | −$9.7M | — |
| Q1 2021 | 2021-03-31 | −$38.6M | −$11.2M | — |
| Q4 2020 | 2020-12-31 | −$24.3M | −$6.5M | — |
| Q3 2020 | 2020-09-30 | −$21.2M | −$4.2M | — |
| Q2 2020 | 2020-06-30 | −$22.8M | −$11.5M | — |
| Q1 2020 | 2020-03-31 | −$27.4M | −$1.5M | — |
| Q4 2019 | 2019-12-31 | −$17.8M | — | — |
| Q3 2019 | 2019-09-30 | −$17.0M | — | — |
| Q2 2019 | 2019-06-30 | −$11.4M | — | — |
| Q1 2019 | 2019-03-31 | −$25.9M | — | — |
Beam Therapeutics operating cash flow trends
Over the last five fiscal years, Beam Therapeutics's operating cash flow decreased from −$95.7M to −$345.1M, a change of −$249.4M. The latest reported quarter, Q2 2026, shows −$66.1M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...